Chiesi 2023 Sustainability Report
CARY, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) — Chiesi (key-A-zee), an international research-focused biopharmaceutical group, announced the release of its 2023 Sustainability Report, available here, which showed the company in 2023 has maintained its aggressive approach to delivering shared value for its stakeholders around the globe. Additionally, Chiesi announced today that its US community engagement focus areas in the US will address patients’ access to care, environmental impacts, food insecurity and STEM education as core enterprise level initiatives.
“As we prepare to begin Chiesi’s 90th year as a company committed to addressing societal challenges as part of our core mission, we are unrelenting in our pursuit to deliver impact to patients, their families, their communities and society,” said Jon Zwinski, general manager, Chiesi USA. “Our 2023 sustainability report demonstrates progress in our goals to adopt ESG measurements in supplier onboarding, protect the planet, and embed sustainability principles further into our business decision-making.”
Looking forward to 2025, Chiesi USA has evolved its acclaimed employee-led program, Chiesi in the Community, to align with four pillars that strive to address social determinants of health that affect patient health outcomes and provide education to ensure continued innovation and diversity of thought:
“At Chiesi, our integrated approach to sustainability is rooted in a profound commitment to long-term planning and collaboration. We understand that tackling the social determinants of health requires a collective effort, which is why our Chiesi in the Community program is so pivotal,” said Sunny Grothaus, shared value and sustainability business partner at Chiesi USA. “By focusing on access to healthcare, food security, environmental health, and STEM education, we aim to address immediate needs while setting a foundation for a healthier future. Our strategic partnerships play a crucial role in this mission, enabling us to drive change and foster opportunities for growth and innovation.”
Sustainability highlights, including those from the 2023 report (available here) include:
PATIENTS – Advancing Innovation and Health Equity to Meet Patient Needs
PLANET – Climate Transition Plan: Achieving Net Zero by 2035
PEOPLE – Prioritizing Wellbeing, Equity, and Community Development
Chiesi fosters an inclusive workplace. This commitment is underscored by certifications like Great Place to Work ™ (GPTW) and Top Employer.
PROSPERITY – Do Good, Do Well, Repeat
Chiesi’s 2023 Sustainability Report has voluntarily undergone an external assurance process in compliance with the Global Reporting Initiative (GRI). GRI is an independent international standards organization that helps businesses understand and communicate their impacts on Environmental, Social, and Governance (ESG) issues. In response to the new European Corporate Sustainability Reporting Directive, Chiesi Group is committed to enhancing its data collection and reporting processes, giving equal importance to financial and sustainability reporting, and ensuring they are aligned and integrated.
About Chiesi USA
Chiesi USA, Inc., headquartered in Cary, North Carolina, is a specialty pharmaceutical company focused on commercialization of products for the hospital and target office-based specialties. Chiesi USA is a wholly owned subsidiary of privately-owned Chiesi Farmaceutici S.p.A, a global R&D-focused pharmaceutical company based in Parma, Italy. In the United States, the company delivers therapies and enhances care for patients in the areas of acute cardiology, neonatology, cystic fibrosis and rare diseases. Recognized as a Certified B Corporation, Chiesi is dedicated to improving the health and wellbeing of its communities through its employee-led corporate social responsibility program, Chiesi in the Community. Innovation, collaboration and impact are the cornerstones of the Chiesi culture. For more information, visit www.chiesiusa.com.
About Chiesi Group
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,000 employees. The Group’s research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For further information please visit www.chiesi.com.
PP-CH-00075 V1.0
Contacts
Chiesi US Media Relations: us.mediarelations@chiesi.com
1 Chiesi Achieves Platinum Medal from EcoVadis: https://www.chiesi.com/en/medal-ecovadis/
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7fcdf986-72b4-40fd-9503-6ef759245646
PDF available: http://ml.globenewswire.com/Resource/Download/59d75fe4-7c6c-4a4d-821f-e5feb225a4aa
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - October 11, 2024)…
SUNNYVALE, Calif., Oct. 10, 2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical…
Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia"…
Most vulnerable sectors include pharmaceuticals, medical devices, agriculture, defense and aerospace WASHINGTON, Oct. 10, 2024…
MIDDLETON, Wis., Oct. 10, 2024 /PRNewswire/ -- Natus Medical Incorporated announced it has submitted an…
Event Draws 100+ Health Systems for 40+ Sessions Focused on Enhancing the Patient Experience Through…